biotech / news / / STAT
The Pharmalot is back for another week of fun and games.
The FDA has proposed excluding semaglutide and tirzepatide from the bulk compounding list.
KEY POINTS
- This move blocks large compounding pharmacies from making versions of Wegovy, Ozempic, Mounjaro, and Zepbound.
- The FDA determined there is no 'clinical need' for compounded semaglutide or tirzepatide products.
- This decision is considered a victory for Novo Nordisk and Eli Lilly, the drugs' manufacturers.
COMPANIES
Summarized by Newsio from STAT. How we summarize →